Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Insurance-related barriers impede L-glutamine access

Publish date:: June 17, 2019

Key clinical point: Adherence to L-glutamine for sickle cell disease was troubled, a study reports.

Major finding: After 10 months, just 21% of patients were still taking the medication.

Study details: Prospective study of 101 patients prescribed L-glutamine and followed over a 10-month period.

Disclosures: Dr. Ogu reported a financial relationship with Vertex.

Citation:

Ogu U et al. FSCDR 2019, Abstract JSCDH-D-19-00041.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in Anemia

Emotions, worse attention linked to pain-related health care use SCD,

Oxidatative stress-related genetic variant tied to stroke risk in sickle cell patients,

Genetic variants may predict stroke in some adult SCD populations,

Severe COVID-19 may lower hemoglobin levels,

Low plasma sodium levels can predict complications in acute painful episodes of SCD,

All Specialties